These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Recombinant human granulocyte colony-stimulating factor after allogeneic bone marrow transplantation.
    Author: Huang X, Guo N, Fan Y, Lu D.
    Journal: Chin Med J (Engl); 1996 Nov; 109(11):827-31. PubMed ID: 9275365.
    Abstract:
    OBJECTIVE: To examine the effect of rhG-CSF on allogeneic bone marrow transplantation. PATIENTS AND METHODS: One hundred and twenty patients with acute or chronic leukemia received HLA-A.B.DR identical and MLC negative sibling donor allo-BMT. Among them, 58 cases of were treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF), while the other 62 cases of the 120 patients were treated as control. RESULTS: Clinical results showed that the time taken to reach an absolute neutrophil count > 0.5 x 10(9)/L was significantly faster in patients who received rhG-CSF compared with control patients (16.24 +/- 0.25 vs 25.20 +/- 0.16 days. P < 0.001), with significantly less early fever days in patients received rhG-CSF (1.17 +/- 1.10 vs 4.01 +/- 0.37 P < 0.001). We did not observe any increase in acute GVHD and relapse in myeloid leukemia patients. But 7 of 16 patients with ALL relapsed after allo-BMT in rhG-CSF group, while only 3 of 11 patients with ALL relapsed after allo-BMT in control grant (P > 0.05). This phenomenon has not been reported up to now. CONCLUSIONS: rhG-CSF can promote engraftment and reduce early fever days after BMT. rhG-CSF has not any effect on a GVHD. The effect of rhG-CSF on leukemia relapse needs to be further studied.
    [Abstract] [Full Text] [Related] [New Search]